91,370 Shares in Biogen Inc (NASDAQ:BIIB) Purchased by Royal London Asset Management Ltd.

Share on StockTwits

Royal London Asset Management Ltd. bought a new position in shares of Biogen Inc (NASDAQ:BIIB) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 91,370 shares of the biotechnology company’s stock, valued at approximately $26,522,000.

Other hedge funds have also bought and sold shares of the company. Financial Gravity Wealth Inc. purchased a new position in shares of Biogen during the first quarter worth $318,000. Neuberger Berman Group LLC boosted its position in shares of Biogen by 2.1% during the first quarter. Neuberger Berman Group LLC now owns 21,256 shares of the biotechnology company’s stock worth $5,824,000 after buying an additional 427 shares during the period. Canandaigua National Bank & Trust Co. purchased a new position in shares of Biogen during the first quarter worth $276,000. Oppenheimer Asset Management Inc. boosted its position in shares of Biogen by 16.7% during the first quarter. Oppenheimer Asset Management Inc. now owns 17,328 shares of the biotechnology company’s stock worth $4,745,000 after buying an additional 2,483 shares during the period. Finally, Anchor Capital Advisors LLC purchased a new position in shares of Biogen during the first quarter worth $1,643,000. 87.46% of the stock is owned by institutional investors.

NASDAQ BIIB traded up $3.67 during trading on Friday, reaching $330.94. 1,022,669 shares of the company’s stock were exchanged, compared to its average volume of 1,633,890. The company has a market capitalization of $71.17 billion, a price-to-earnings ratio of 15.17, a price-to-earnings-growth ratio of 1.36 and a beta of 0.86. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.36 and a quick ratio of 2.06. Biogen Inc has a 1 year low of $249.17 and a 1 year high of $388.67.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Tuesday, July 24th. The biotechnology company reported $5.80 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $5.22 by $0.58. The company had revenue of $3.36 billion during the quarter, compared to the consensus estimate of $3.25 billion. Biogen had a return on equity of 38.17% and a net margin of 23.06%. Biogen’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the business earned $5.04 EPS. As a group, equities research analysts expect that Biogen Inc will post 25.34 earnings per share for the current year.

In other Biogen news, EVP Michael D. Ehlers sold 1,000 shares of Biogen stock in a transaction dated Wednesday, September 26th. The stock was sold at an average price of $350.00, for a total transaction of $350,000.00. Following the completion of the sale, the executive vice president now directly owns 4,281 shares of the company’s stock, valued at approximately $1,498,350. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.29% of the stock is owned by insiders.

BIIB has been the subject of several research analyst reports. ValuEngine upgraded Biogen from a “hold” rating to a “buy” rating in a research report on Tuesday, July 24th. BidaskClub upgraded Biogen from a “hold” rating to a “buy” rating in a research report on Friday. Oppenheimer set a $400.00 price target on Biogen and gave the stock a “buy” rating in a research report on Sunday, July 8th. UBS Group raised their price target on Biogen from $354.00 to $395.00 and gave the stock a “buy” rating in a research report on Thursday, July 26th. Finally, Robert W. Baird lowered Biogen from an “outperform” rating to a “neutral” rating and set a $323.00 target price for the company. in a report on Tuesday, July 10th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and twenty-three have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $381.31.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.

Featured Article: Discount Rate

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.